News
September 2017
Welcome Thomas Cogswell
A very warm welcome to Thomas Cogswell who joined the group (1st Sept) as an OxStem Oncology-funded PDRA working on the development of small molecules to promote differentiation of cancer stem-like cells to more benign states.
August 2017
Welcome Jessica Rowley
We are delighted to welcome Jessica Rowley to the group (14th August) who will be working on small molecule modulators of utrophin for Duchenne Muscular Dystrophy therapy, a project in collaboration with Professor Dame Kay E. Davies (Department of Physiology, Anatomy and Genetics, University of Oxford) and Summit Therapeutics plc.
Stacks Image 4968
Poster Prize for Aini Vuorinen
Aini Vuorinen, a Muscular Dystrophy UK-funded DPhil student in Angela Russell’s group, has been awarded a poster prize at 11th European Summer School - Advanced Proteomics in Bressanone, Italy (30th July to 5th August). The international workshop provided a comprehensive insight into proteomic technologies and applications in the life science. Aini presented aspects of her work using chemoproteomics to elucidate the molecular mechanism of action of small molecule modulators of utrophin for Duchenne Muscular Dystrophy Therapy.
July 2017
Welcome Fern Woodhouse
A very warm welcome to Fern who joins the AJR group on 17th July on her second SABS-CDT rotation project.
Presentation: AJR at Lilly 50 Years of Research at Erl Wood
AJR was invited to speak at Lilly's celebratory symposium entitled 'The next 50 years of neuroscience research' on 14th July. Her talk described the current research within the group to discover new drug candidates towards a new therapeutic strategy for the treatment of neurodegenerative and neuropsychiatric disorders.
June 2017
Welcome Lim Zhong Hui
A very warm welcome to Lim who joins the AJR group on 19th June for an 8-week summer vacation placement working on OxStem-funded research project.
Welcome Ieva Ragaisyte
A very warm welcome to Ieva who joins the team for a 4-week summer vacation placement starting on 3rd June.
May 2017
OxStem Ltd featured in Nature
OxStem Ltd, a University of Oxford spin-out company co-founded by Professor Steve Davies and Prof. Angela Russell, is featured in the May 2017 issue of Nature in an article entitled “Masters of Medicine”. OxStem was selected as one of six innovative and disruptive University start-up biotechnology companies from around the world to be profiled in the article. Read more…
Stacks Image 4937
Stacks Image 4946
Stacks Image 4940
Stacks Image 4927
Team 'Russell's Muscles' complete the Town and Gown Race
Well done to the 'Russell's Muscles' team (Morgan Jay Smith, Aini Vuorinen, Tom Carter, Liam Bromhead, Laura Mola Sola, Dominic Faulkener, Daniel Conole, and friends) who successfully ran the Oxford 10-km road race on Sunday 14th May. The event, held annually, is organised by the Muscular Dystrophy UK charity.
Stacks Image 4930
Running the Town and Gown 10km - Russell's Muscles
On Sunday 14th May some members of the AJR group are participating Oxford Town and Gown 10 km run which is organised by, and in aid of, Muscular Dystrophy UK. Please come along to support the team Russell's muscles and Muscular Dystrophy UK. For more information please follow the link http://www.townandgown10k.com/oxford/
April 2017
Welcome Irene Georgiou
We are very pleased to welcome Irene Georgiou who has joined the AJR group as an OxStem Cardio-funded PDRA.
March 2017
Women in Science blog
Professor Angela Russell is currently featured on Oxford ScienceBlog’s Women in Science series. She was interviewed about her career in science and entrepreneurship as part of International Women in Science Day 2017. Read the full blog.
Welcome to new members of the group
A very warm welcome to Jens Schmidt and Chris Greaves who join the AJR group as PDRAs working on OxStem-funded research programmes.
Women in Science Day
To celebrate Women in Science Day (8th March 2017), AJR will be presenting 'From Chemistry to Stem Cells: My Scientific Journey', in the Library at the Sherington Building, DPAG; 4pm.
Presentation: AJR at SelectBio: Stem Cells in Drug Discovery conference, Cambridge
AJR was invited to speak in Cambridge at the SelectBio: Stem Cells in Drug Discovery conference on Monday 6th March. Her presentation is entitled 'Medicinal Chemistry in Regenerative Medicine: Discovery of in vivo-active Small Molecule Modulators of Endogenous Stem Cells'.
AJR presents her Departmental (Organic Chemistry) Colloquium today
Prof Angela Russell will be speaking today, Thursday 2nd March, 2pm on 'Chemistry for regenerative medicine: Discovery of small molecules to manipulate (stem) cell fate' in the Dyson Perrins building, South Parks Road.
February 2017
Welcome Liam Bromhead
A very warm welcome to Liam who joins the group (20th February) who is an OxStem-funded PDRA.
Welcome Enrico Emer
We are very pleased to welcome Enrico Emer to the group (13th February). He is an OxStem-funded PDRA who will be working on the OxStem Cardio research programme.
Celebrating International Day of Women and Girls in Science
Standing alongside other female researchers from the University, AJR has been featured in a blog to inspire the next generation of women scientists. Read more…
January 2017
AJR interviewed on BBC South Today
Broadcast on 13th January, Professor Angela Russell was interviewed for regional news programme BBC South Today. Co-founded by Prof. Steve Davies and Prof. Angela Russell, Oxford spin-out OxStem Ltd was highlighted as a major success story for Oxford University Innovation (“OUI”), the University of Oxford’s technology transfer office. OUI celebrated a record-breaking year in 2016 facilitating 24 spin-out companies representing £52.6m of investment; five of the 24 new spin-outs were OxStem companies, amounting to £16.9m of the total investment into the University.
Stacks Image 4896
Congratulations Dr Caitlin Clunie-O'Connor
Well done to Caitlin who successfully passed her DPhil on 12th January.
Welcome to new members of the team
We are very pleased to welcome Morgan Jay-Smith, Katrina Madden and Tom Carter to the group, all PDRAs funded under OxStem research programmes. We would also like to welcome visiting PhD student Laura Guidotti from the University of Bologna, undertaking a 6-month research project in collaboration with Prof Francis Szele at DPAG.
December 2016
Welcome Erin
A very warm welcome to Erin Shepherd who joins the AJR group as an OxStem-funded PDRA working on the OxStem Neuro research programme (5th December).
November 2016
BioBeat 2016 blog
Following her nomination as a 'rising star' in the BioBeat 2016 'Movers and Shakers' report and participation in the BioBeat16 Summit, AJR comments in the event blog.
Stacks Image 1412
OxStem Cardio launched
A fourth subsidiary of OxStem Ltd, an Oxford spin-out co-founded by Prof. Steve Davies and Prof. Angela Russell has been launched (17th November 2016). OxStem Cardio, co-founded with Prof. Roger Patient (Professor of Developmental Genetics Weatherall Institute of Molecular Medicine) and Prof. Paul Riley (British Heart Foundation Professor of Regenerative Medicine), aims to identify drugs that will restore lost tissue following a heart attack by inducing cardiovascular regeneration, in order to improve cardiac function. This collaborative project will be funded within the University over the next three years following OxStem’s record £16.9M initial fundraise earlier this year. Full press release.
Welcome Sebastien and Laura!
A very warm welcome to Laura Mola Sola and Sebastien Galan, OxStem-funded PDRAs, who joined the group on 14th November.
Stacks Image 4879
BioBeat Movers and Shakers 2016
Prof Angela Russell has been named as a ‘Rising Star’ in the BioBeat 50 Movers and Shakers in BioBusiness 2016 report. Released annually, the report celebrates 50 outstanding women entrepreneurs and business leaders who are recognised for their contributions to global health innovation. BioBeat’s founder Miranda Weston-Smith said that the report highlights those women who are “transforming today’s challenges into tomorrow’s opportunities” and are inspirational “pioneers who are setting the pace in laboratories, healthcare, entrepreneurial companies …“ among others.

Angela Russell, Associate Professor of Medicinal Chemistry at the Departments of Chemistry and Pharmacology at the University of Oxford and co-founder of OxStem Ltd (www.oxstem.co.uk) said “I am delighted to have been recognised in this report standing alongside some exceptional bioscience business leaders in the field. Our research at OxStem has the potential to impact on the healthcare of millions worldwide with the approach of developing small molecule drugs in a wide range of therapeutic areas including cancer, neurodegenerative diseases and heart failure. I hope that my nomination, together with the women featured in this report, helps to inspire the next generation of bioscience entrepreneurs”.
October 2016
Welcome Laia and Purnima!
We are pleased to welcome Laia Josa Culleré who joins the group as a PDRA to work on an OxStem Oncology-funded project to develop new small molecules to promote differentiation of cancer stem-like cells to more benign states. Also working on the project, we are pleased to welcome Purnima Kumar who begins her Pharmacology DPhil programme this month.
Stacks Image 1386
OxStem Ltd wins Best Start-up Biotech Company Award
We are delighted to have been awarded the Best Biotech Start-up Company Award for OxStem Ltd at the Oxfordshire Bioscience Network (OBN) Awards ceremony last night (6th October). The awards, held annually, celebrate innovation and achievement in the UK Life Sciences across Biotech, Medtech, Synthetic Biology and Digital Health categories. John Harris, CEO of OBN, said: "We are thrilled with the high quality of nominees this year which made picking just one winner in each category very difficult”. The company was recognised for it's disruptive approach to the field of regenerative medicine.
Summit Therapeutics plc and Sarepta Therapeutics plc announce exclusive license and collaboration agreement
Today (4th October) Summit Therapeutics and Sarepta Therapeutics have announced that they have entered into an exclusive license and collaboration agreement to advance the development of therapies for the treatment of DMD. The agreement gives Sarepta Therapeutics rights in Europe, Turkey and the Commonwealth of Independent States to Summit's utrophin modulator pipeline including lead candidate ezutromid; Summit retains rights in all other countries. Summit will receive an upfront payment of $40 million, with future ezutromid related development, regulatory and sales milestones payments totalling up to $522 million. The complementary partnership supports the development of innovative and novel therapies to treat patients with the progressive muscle-wasting disease. For more information, click here to read the press release.
September 2016
Welcome Part II students
Welcome to our new Part IIs: Dominic Faulkner, Ria Dinsdale and Sam Exton.
August 2016
Awards nomination for OxStem Ltd
OxStem Ltd is delighted to have been short-listed for the award of 'Best Start-up Biotech Company' at the OBN Awards 2016. The winner will be announced on 6th October 2016.

For more information, see: http://www.obn-awards.com/
Stacks Image 2555
Stacks Image 2557
Stacks Image 2559
Stacks Image 3723
OxStem Neuro and OxStem Ocular launched
Two new subsidiaries of OxStem Limited, an Oxford spin-out co-founded by Prof. Angela Russell and Prof. Steve Davies, were launched (4th August). OxStem Neuro, co-founded with Prof. Francis Szele (Physiology, Anatomy and Genetics), aims to identify drugs that will stimulate de novo neuron production from neural stem cells that will compensate for disease pathology in neurodegenerative diseases, stroke and traumatic brain injury. OxStem Ocular, co-founded with Prof. Robert MacLaren (Nuffield Laboratory of Ophthalmology), aims to identify drugs that will stimulate precursor cells within the retina of patients for retinal repair and restoration of vision. These two collaborative projects will be funded within the University over the next three years following OxStem’s record £16.9M initial fundraise in May 2016. Click here for further information.
Welcome Bridget Reeve
We are pleased to welcome Bridget who, during her 4-week summer vacation placement starting on 1st August, will be working on a project investigating small molecule modulators of neurogenesis.
Congratulations Daniel and Jack
Well done to Jack Hoffman (St John's College) and Daniel Sowood who have won Organic Chemistry prizes for their excellent work this year. Jack has won a prize for his Part II thesis and Daniel has won a Turbutt Prize for 2nd year Organic Chemistry practicals.
July 2016
Welcome Alastair Baldry
Alastair joins us on 25th for a summer vacation placement, welcome!
Welcome Lewis and Jakub
We are pleased to welcome Jakub Stefaniak and Lewis O'Shaughnessy into the group this week. Jakub, a SABS-CDT student, starts his second rotation project in our group in association with the Target Discovery Institute. Lewis begins his 8-week BHF CRE-funded project to elucidate the mechanism of action of small molecule activators of epicardial cells in development and tissue regeneration.
Welcome Ben Saward
Ben Saward joins us on 11th July for a summer vacation placement, welcome!
June 2016
Congratulations
Congratulations to Ryan Davies, Samantha Cloake and Jessica Reynolds for handing in their Part II theses.
Welcome Sebastian and Imogen
A very warm welcome to Imogen Bentham and Sebastian Orbell who join us this week for their summer vacation placements starting 20th June.
Medicinal chemistry resource
The latest version of the Drug Discovery Glossary by Steve Davies, Peter Kennewell, Angela Russell, Robert Westwood and Graham Wynne is available to download and review from the 'teaching' page of this website.
May 2016
Presentation: AJR at ESBOC
AJR was invited to present her talk on "Chemistry for regenerative medicine: discovery of small molecules to manipulate stem cell fate" at the European Symposium on Biological and Organic Chemistry: a Celebration of Biological and Organic Chemistry on 20th May.
Publication: Chemical-induced Naive Pluripotency
AJR (with Laurence Silpa) was invited to submit a commentary this month in Cell Chemical Biology to review two papers by Ursu et al. and Illich et al. demonstrating that inhibition of a CK1 isoform efficiently induces naive pluripotency in epiblast stem cells. Access online...
Stacks Image 2492
Supporting the Duchenne Dash team - 12th May 2016
A team of cyclists named 'Duchenne Dash' is currently undertaking an arduous 1,000 mile journey from John O'Groats to Paris in order to raise money for the Duchenne Children's Trust - to fund vital research into the progressive muscle wasting disorder Duchenne Muscular Dystrophy (DMD). The DMD research teams from the Russell and Davies' laboratories showed their support by welcoming them at the Blenheim Palace grounds, together with former England rugby captain Will Carling and former Olympic rower Greg Searle.

Stacks Image 1258
OxStem's record fundraising round featured in Financial Times
The Financial Times today (11/05/16) features OxStem in an article about it's record investment round and the groundbreaking research that will be funded as a result. The story highlights the importance of unlocking the potential of research from UK universities to translational medicine; OxStem will address a number of therapeutic areas in regenerative medicine including cancer, heart failure and neurodegenerative diseases. The article is published on page 4 of today's edition of the Financial Times. FT subscribers can also read the article online.
Stacks Image 1253
Record £16.9M Oxford spin-out designing stem cell drugs to treat age-related disease
OxStem, an Oxford spin-out founded by Prof. Angela Russell, Prof. Steve Davies (Department of Chemistry) and Prof. Dame Kay Davies (Department of Physiology, Anatomy and Genetics), has raised a record £16.9M to develop small molecule drug candidates to treat age-related conditions including cancer, neurodegenerative diseases and heart failure. The company has formed strategic partnerships with Human Longevity Inc. and CEO Dr J Craig Venter together with Mr Bob Duggan and Dr. Mahkam Zanganeh (former CEO & Chairman and Chief Operating Officer respectively) of Pharmacyclics that was sold last year to Abbvie for US$21 billion. Other individual investors, together with Oxford Science Innovation, will enable OxStem to fund the development of a series of daughter companies - each with a focus on a different large unmet therapeutic need. The majority of the £16.9M is expected to be used to fund joint projects between the Department of Pharmacology, the Department of Chemistry and other Departments across Oxford over the next three years. Read more…
April 2016
Welcome Isabel Wilkinson
A warm welcome to Isabel, a SABS-CDT student (www.sabscdt.ox.ac.uk), who joined our group on 11th April to work on the utrophin modulation drug discovery programme.
March 2016
Summit Therapeutics plc announces positive interim data in ongoing phase I clinical trial with SMT C1100.
The company announced (30/3) that evaluation of a new oral formulation of the lead utrophin modulator SMT C1100 shows improvements in patients with DMD over their current formulation. Read more...
Well done Anna
Congratulations to Anna Olerinyova who submitted her Part II thesis on 29th March.
February 2016
Welcome Daniel Conole
A very warm welcome to Daniel Conole who joins the AJR group to work on small molecule modulators of utrophin for Duchenne Muscular Dystrophy therapy, a project in collaboration with Professor Dame Kay E. Davies (Department of Physiology, Anatomy and Genetics, University of Oxford) and Summit Therapeutics plc.
Muscular Dystrophy UK spotlights our research towards new treatments for DMD
Our work on the elucidation of the mechanism of action of small molecule modulators of utrophin for the treatment of Duchenne Muscular Dystrophy, is being featured by Muscular Dystrophy UK this month. The charity funds the research project by Aini Vuorinen in collaboration with Professor Dame Kay Davies and Professor Steve Davies.
January 2016
Commendation for James Egleton
Congratulations to James who was awarded a special commendation from the MPLS Divisional Board for producing an excellent thesis.
Presentation: AJR at the University of St. Andrews
AJR was invited to present her talk on "Chemistry for regenerative medicine: small molecules to manipulate stem cell fate" at the Biomedical Research Complex at the University of St. Andrews on 27th January.
December 2015
Well done Dr Varney!
Congratulations to Amy who successfully passed her DPhil viva on 4th December.
Summit Therapeutics plc announces first research milestone achieved in strategic alliance
The company has announced that two series of novel utrophin modulators have been nominated to progress into lead optimisation studies, achieving the first research milestone as part of the strategic alliance. The partnership aims to develop utrophin modulators for the treatment of patients for the progressive muscle-wasting disease Duchenne Muscular Dystrophy (DMD). Read more...
November 2015
Congratulations Dr Egleton!
Well done to James who successfully passed his DPhil viva on 26th November.
Multi-year £3.3M extension of strategic alliance with Summit Therapeutics plc
Summit Therapeutics plc has announced a multi-year extension of its exclusive strategic alliance with the research teams of Prof Angela Russell, Prof Steve Davies and Prof Dame Kay Davies (DPAG) until November 2019, with an option to extend it for a further 12 months, to support and accelerate development of future generation utrophin modulators for the treatment of the progressive muscle wasting disorder, DMD. Summit Therapeutics will continue to sponsor a drug discovery and development programme in the University of Oxford research laboratories to identify and develop oral utrophin modulators for the treatment of DMD. This research programme, originally running to November 2016, will now continue until November 2019 with a option to extend it for a further 12 months. As part of the extension, Summit Therapeutics will increase the funding to £0.83 million a year starting in November 2015. More...
Publication: The Derivation of Primary Human Epicardium-Derived Cells
Congratulations to Caitlin on her new Current Protocols in Stem Cell Biology paper this month describing techniques to establish and maintain human epicardium explant cultures from patient-derived right atrial appendage biopsies and methods to probe the resultant outgrowth of human epicardium-derived cells (hEPDCs). Access online...
Publication: Augmentation of creatine in the heart
A paper has been published in Mini-reviews in Medicinal Chemistry discussing the evidence in support of creatine elevation and the pharmacological approaches currently available. Access online...
October 2015
Thesis submission - Amy Varney
Congratulations to Amy who has submitted her thesis this month.
Welcome Christopher Lindsay and Daniel Lucy
Welcome to the AJR group, Chris and Daniel who are beginning their British Heart Foundation (BHF) Centre of Research Excellence DPhil in Medicinal Chemistry for Cardiovascular Disease on 1st October.
September 2015
Welcome Part II students
Welcome to our new Part IIs: Samantha Cloake, Ryan Davies, Anna Olerinyova and Jessica Reynolds.
Presentation: Graham Wynne at RSC-SCI Medicinal Chemistry symposium
Graham presented a talk entitled 'Discovery of compounds which modulate utrophin expression for the treatment of Duchenne Muscular Dystrophy' at the 18th SCI/RSC Medicinal Chemistry conference in Cambridge on 16th September.
August 2015
Presentation: AJR at the American Chemical Society (ACS) 250th meeting - Boston
AJR gave a presentation entitled 'Discovery of small molecule utrophin modulators for the therapy of Duchenne Muscular Dystrophy (DMD)' on Sunday 16th August at the celebratory 250th ACS meeting: Innovation - from Discovery to Application.
Summit Therapeutics plc announces Phase 1b clinical trial success
On 17th August, Summit Therapeutics revealed that their primary objective for the Phase 1b Modified Diet clinical trial of SMT C1100 for the treatment of Duchenne Muscular Dystrophy (DMD) had been achieved. The compound has received orphan drug designation in the US and Europe and will be progressed to Phase 2 open-label trial in 4Q2015. To read more about this story, click here. See also www.summitplc.com.
Welcome Maria Chatzopoulou
Maria has joined the AJR group to work on small molecule modulators of utrophin for Duchenne Muscular Dystrophy therapy, a project in collaboration with Professor Dame Kay E. Davies (Department of Physiology, Anatomy and Genetics, University of Oxford) and Summit Therapeutics plc.
Welcome Karen Heathcote
Karen has joined our group for four weeks, from 3rd August, to work on small molecule modulators of utrophin for Duchenne Muscular Dystrophy therapy, a project in collaboration with Professor Dame Kay E. Davies (Department of Physiology, Anatomy and Genetics, University of Oxford) and Summit Therapeutics plc.
Welcome Minjun Yang
Minjun joins us for his summer vacation sponsored placement starting 1st August, for eight weeks. Minjun is working, in collaboration with David Greaves of the BHF Centre of Research Excellence, on small molecule modulators of chemotaxis.
Moving on to pastures new - Gu Liu
Gu Liu has left the group to join Accenture - although sad to see her leave, we wish her the best of luck in her new role.
July 2015
Thesis submission - James Egleton
Well done to James who has submitted his thesis this month.
Stacks Image 1067
Dr Kristína Csatayová
The department is very sad to announce that Dr Kristína Csatayová died on 26th July at the age of 32. Kristína secured her DPhil under the supervision of Professor Steve Davies last year, and was a postdoctoral research assistant to both Steve Davies and Angela Russell. She will be remembered for her outstanding contribution to chemistry and for being an exceptional scientist and human being. She will be greatly missed amongst her peers, friends and families. A donation to the Sobell House Hospice Charity (https://www.justgiving.com/Kristina-Csatayova) would be a wonderful way to support a cause that is important to her family and friends, and to honour Kristína who lost her life after a fierce battle with cancer.
Welcome Daniel Sowood
In collaboration with Prof. David Sattelle (UCL) and Prof. Kathryn Else (University of Manchester), Daniel will be working on an anti-parasitic agent project during his summer vacation placement starting on 24th July, for 10 weeks.
Welcome Jonathan Taylor
Jonathan joins us for his summer vacation placement starting 13th July, for seven weeks. He'll be working with Caitlin on the British Heart Foundation funded project to support the development of high throughput screening assays to identify small molecule activators of the resident progenitor cells of the human adult epicardium.
Prize: Robyn Zorab
Congratulations Robyn - after successfully completing her Part II, she was awarded the Examiners' Special Prize for Chemical Biology. The prize signifies the culmination of her hard work over the last year and so well done Robyn!
Stacks Image 1020
Congratulations!
Well done to Marcus, Josh, Robyn and Jessica who have recently completed their Part II projects.
Welcome Bruno Marinic
In collaboration with Prof. David Sattelle (UCL) and Prof. Kathryn Else (University of Manchester), Bruno will be working on an anti-parasitic agent project during his summer vacation placement starting on 1st July, for 5 weeks.
June 2015
Welcome Dr. Laurence Silpa
We are pleased to announce that Dr. Laurence Silpa will be joining the group on 15th June to work on an EU Innovative Medicines Initiative (IMI) funded project, part of the Oxford-led StemBANCC consortium. Building on the work of Gu Liu, Laurence's project will focus on small molecule manipulation of induced pluripotent stem cells.
May 2015
Publication: second generation compound with exciting potential for the treatment of DMD
A new Human Molecular Genetics paper highlights some exciting results of the second generation compound, SMT 022357, shown to have utrophin modulation activity for the potential treatment of Duchenne Muscular Dystrophy. The compound, through an established mouse model, has exhibited improved physiochemical properties and a more robust metabolism profile than the original compound. These results support the continued development of the compound for the treatment of the lethal, muscle-wasting disease. Access online.
Stacks Image 960
Welcome Dr. Nicky Willis
We are pleased to welcome Dr. Nicky Willis to the group. He'll be working on a Summit Therapeutics-funded project optimising utrophin modulators for Duchenne Muscular Dystrophy therapy. Nicky joins us following a post-doctoral project at GlaxoSmithKline, in collaboration with Prof. Graham Sandford (University of Durham).
April 2015
Stacks Image 947
Presentation at the 10th Annual Drug Discovery Chemistry Conference
Amy Varney was invited to give an oral presentation at the Drug Discovery Chemistry Conference in San Diego, CA. following the submission of her poster entitled 'Methylation and Cancer: Inhibiting the PRMTs and looking for new epigenetic markers'. The conference, in it's tenth year invited medicinal chemists from Pharma and Biotech to enjoy presentations and posters featured in six key themes (Protein-Protein Interactions; Inflammation Inhibitors; Kinase Inhibitor Chemistry; Macrocyclics and Constrained Peptides; Fragment-based Drug Discovery; and Epigenetic Inhibitor Discovery, where Amy's work was featured).
March 2015
Stacks Image 934
Muscular Dystrophy UK research team visit
We were delighted to welcome the CEO, Robert Meadowcroft, and representatives of Muscular Dystrophy UK to the CRL, early this month, to provide them with an update on the work being done on the utrophin modulation programme. Meetings were held throughout the day and a presentation given by Aini Vuorinen on her recent work on newly identified compounds that modulate the up-regulation of utrophin. To read more about the visit, take a look at the news item on the Muscular Dystrophy UK website by clicking here.
January 2015
Stacks Image 845
Revealing a new drug development strategy
A recent paper in the Journal of Medicinal Chemistry introduces an emerging new paradigm 'Stemistry' for the search and development of new agents targeting resident stem cells involved in repair processes in the tissues they exist. Access online.
Stacks Image 858
A new class act: front cover highlights cannabinoid receptor work
A paper on work identifying a new class of selective cannabinoid receptor 2 (CB2R) agonists was chosen for the front cover image by Bioorganic and Medicinal Chemistry. The featured paper describes new CB2R activating molecules which have promise for further in vitro and in vivo studies, leading to the new development of drug candidates with potential for the treatment of a range of inflammatory diseases, including atherosclerosis and arthritis. Access online.